YIH
ELTX icon

Y-Intercept (HK)’s Elicio Therapeutics ELTX Stock Holding History

Y-Intercept (HK)’s Portfolio ELTX Stock Details ELTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-1,116
Closed -$13K – 1054
2022
Q2 		$13K Buy
+1,116
New +$17.8K ﹤0.01% 805

Other funds holding ELTX

BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CM
CM Management Gulf Breeze, Florida $120M AUM 37.12% 1-Year Est. Return
PWAM
Park West Asset Management San Francisco, California $1.18B AUM 47.25% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
E
Ergoteles New York $68.2M AUM 36.16% 1-Year Est. Return

Y-Intercept (HK)'s ELTX Position: Q3 2022 in Review

Y-Intercept (HK) sold out of Elicio Therapeutics (ELTX) in Q3 2022, closing a stake of 1,116 shares — an estimated $13K sold.

Y-Intercept (HK) first reported a position in ELTX in Q2 2022 and held it in 1 quarter. The position peaked at $13K in Q2 2022. 38 funds tracked by Wall St. Rank hold ELTX as of Q3 2022.

  • Y-Intercept (HK) reported no remaining Elicio Therapeutics position as of Q3 2022 after selling out during the quarter.
  • Y-Intercept (HK) sold 1,116 Elicio Therapeutics shares in Q3 2022, an estimated $13K.
  • Y-Intercept (HK) first reported a position in Elicio Therapeutics in Q2 2022 and held it in 1 quarter.
  • Y-Intercept (HK)'s Elicio Therapeutics position peaked at $13K in Q2 2022.
  • 38 funds tracked by Wall St. Rank held Elicio Therapeutics as of Q3 2022.

Based on Y-Intercept (HK)'s 13F filing for Q3 2022, filed 14 Feb 2023.